Stockscreener 앱 받기
14.40
1.55%
0.25
전일 마감가:
$14.15
열려 있는:
$14.15
하루 거래량:
126.32K
Relative Volume:
0.13
시가총액:
$584.93M
수익:
-
순이익/손실:
$-168.05M
주가수익비율:
-2.807
EPS:
-5.13
순현금흐름:
$-146.15M
1주 성능:
-1.37%
1개월 성능:
-1.91%
6개월 성능:
-74.67%
1년 성능:
-69.34%
1일 변동 폭
$14.15
$14.74
1주일 범위
$13.77
$14.91
52주 변동 폭
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
명칭
Keros Therapeutics Inc
전화
617-314-6297
주소
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
KROS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
14.40 | 582.83M | 0 | -168.05M | -146.15M | -5.13 |
|
ONC
Beone Medicines Ltd Adr
|
244.83 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.62 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.45 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.76 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-12-16 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-16 | 재확인 | Oppenheimer | Outperform |
| 2024-12-13 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-12 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-12-12 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-12-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 개시 | Jefferies | Buy |
| 2024-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-23 | 개시 | Guggenheim | Buy |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-02-21 | 개시 | William Blair | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-07-31 | 개시 | Wedbush | Outperform |
| 2023-07-26 | 개시 | BofA Securities | Buy |
| 2023-02-14 | 개시 | Cowen | Outperform |
| 2022-10-18 | 개시 | Truist | Buy |
| 2022-07-26 | 개시 | BTIG Research | Buy |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2020-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.9%Should You Sell? - MarketBeat
ProShare Advisors LLC Purchases 2,764 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Bank of America Corp DE - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,386 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics' (KROS) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat
Deutsche Bank AG Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics (NASDAQ:KROS) Receives Neutral Rating from Wedbush - Defense World
D. E. Shaw & Co. Inc. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN
KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | - GuruFocus
TFG Asset Management GP Ltd Acquires New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics halts PAH drug development, cuts workforce By Investing.com - Investing.com South Africa
Janus Henderson Group PLC Has $226,000 Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being - simplywall.st
Keros Therapeutics Shares Drop; Cibotercept Development Halted, Jobs Cut - marketscreener.com
KROS Halts Development of Cibotercept in PAH After Safety Concer - GuruFocus
Keros Therapeutics Announces Corporate Restructuring - citybiz
Keros Therapeutics (KROS) Restructures Focus, Faces Modest Cost Savings | KROS Stock News - GuruFocus
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% - Yahoo Finance
Keros stock as mid-stage trial for PAH therapy ends (KROS) - Seeking Alpha
Keros Therapeutics, Inc. Announces Corporate Restructuring - marketscreener.com
Keros Therapeutics Announces Tropos Topline Data And Corporate Restructuring - marketscreener.com
Keros Therapeutics, Inc. Announces TROPOS Topline Data - marketscreener.com
Keros Therapeutics halts PAH drug development, cuts workforce - Investing.com Australia
KROS Announces Workforce Reduction and Strategic Evaluation | KROS Stock News - GuruFocus
Keros Therapeutics halts cibotercept development, plans workforce reduction By Investing.com - Investing.com Canada
Keros Therapeutics Discontinues Cibotercept Development in PAH and Announces Corporate Restructuring - Nasdaq
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring - Yahoo Finance
1 Stock That Turned $1,000 Into $32 Million - The Globe and Mail
Woodline Partners LP Has $6.14 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
D. E. Shaw & Co. Inc. Sells 174,189 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Millennium Management LLC Raises Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros secures Glass Lewis support for director nominees By Investing.com - Investing.com South Africa
BNP Paribas Financial Markets Invests $730,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Northern Trust Corp Buys 30,111 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros secures Glass Lewis support for director nominees - Investing.com Australia
Keros Therapeutics Urges Stockholders to Vote "FOR" Director Nominees Amid Proxy Contest with ADAR1 - Nasdaq
Leading Independent Proxy Advisory Firm Glass Lewis - GlobeNewswire
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of ... - Bluefield Daily Telegraph
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees - GlobeNewswire Inc.
Keros Therapeutics (KROS) Target Price Adjusted by BofA Analyst | KROS Stock News - GuruFocus
Twinbeech Capital LP Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
(KROS) Trading Signals - news.stocktradersdaily.com
3 Brilliant Stocks to Buy With $200 and Hold for 5 Years - The Globe and Mail
Janus Henderson Group PLC Sells 77,803 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
TFG Asset Management GP Ltd Acquires Shares of 103,000 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Tema Etfs LLC Makes New $565,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $37.00 Average Target Price from Analysts - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Northern Trust Corp Increases Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics Inc (KROS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Keros Therapeutics Inc 주식 (KROS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
0.30 |
49,367 |
14,810 |
302,223 |
| GORDON CARL L | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
| ORBIMED ADVISORS LLC | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
1.76%
0.89%
자본화:
|
볼륨(24시간):